Evidence map›Paper›PMID 32945347›Full record

ArticleInternational journal of molecular medicine2020

Icariside II protects cardiomyocytes from hypoxia‑induced injury by upregulating the miR‑7‑5p/BTG2 axis and activating the PI3K/Akt signaling pathway.

Dongxia Hu, Yong Gu, Dan Wu, Juanjuan Zhang, Qing Li, Jun Luo, Shaochuan Li, Zhen Yuan, Bo Zhu

Open access · hybridAbstract read
In one paragraph

Article in International journal of molecular medicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed, 1 pooled it
0.7field-weighted citation impact, top 33% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 1 synthesis or guideline pooled it, 16 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Review
  5. Review
  6. Article
  7. Review
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 1 country.

Dongxia HuDepartment of Rehabilitation, The Second Affiliated Hospital of Nanchang University, Nanchang, Jiangxi 330321, P.R. China.
Yong GuDepartment of Clinical Laboratory, Jiangxi Thoracic Hospital, Nanchang, Jiangxi 330321, P.R. China.
Dan WuDepartment of Neurology, Nanchang Hongdu Hospital of TCM, Nanchang, Jiangxi 330321, P.R. China.
Juanjuan ZhangDepartment of Rehabilitation, The Second Affiliated Hospital of Nanchang University, Nanchang, Jiangxi 330321, P.R. China.
Qing LiDepartment of Cardiology, The Second Affiliated Hospital of Nanchang University, Nanchang, Jiangxi 330321, P.R. China.
Jun LuoDepartment of Rehabilitation, The Second Affiliated Hospital of Nanchang University, Nanchang, Jiangxi 330321, P.R. China.
Shaochuan LiDepartment of Rehabilitation, The Second Affiliated Hospital of Nanchang University, Nanchang, Jiangxi 330321, P.R. China.
Zhen YuanDepartment of Rehabilitation, The Second Affiliated Hospital of Nanchang University, Nanchang, Jiangxi 330321, P.R. China.
Bo ZhuDepartment of Cardiology, The Second Affiliated Hospital of Nanchang University, Nanchang, Jiangxi 330321, P.R. China.
Second Affiliated Hospital of Nanchang University · CNNanchang University · CNJiangxi Chest Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Icariside II (ICS II) has been reported to have protective effects against oxidative stress. However, whether ICS II protects cardiomyocytes from myocardial infarction (MI), and the associated underlying mechanisms, remain to be elucidated. Therefore, the current study investigated the effects of ICS II on hypoxia‑injured H9c2 cells, as well as the associated molecular mechanisms. A hypoxic injury model was established to emulate the effects of MI. The effects of ICS II on the proliferation of rat cardiomyocyte H9c2 cells were assessed with cell counting kit‑8 assays. The apoptotic status of the cells was assessed by flow cytometry, and the expression of apoptosis‑related proteins was analyzed by western blotting. A microRNA (miRNA/miR) microarray was used to quantify the differential expression of miRNAs after ICS II treatment, and the levels of miR‑7‑5p were further quantified by reverse transcription‑quantitative PCR. Whether ICS II affected hypoxia‑injured cells via miR‑7‑5p was subsequently examined, and the target of miR‑7‑5p was also investigated by bioinformatics analysis and luciferase reporter assays. The effects of ICS II on the PI3K/Akt pathway were then evaluated by western blot analysis. Hypoxia treatment decreased viability and the migration and invasion abilities of H9c2 cells, and also induced apoptosis. ICS II significantly increased viability and reduced hypoxia‑associated apoptosis. Moreover, ICS II treatment led to the upregulation of miR‑7‑5p, and the protective effects of ICS II were found to rely on miR‑7‑5p. Moreover, BTG anti‑proliferation factor (BTG2) was identified as a direct target of miR‑7‑5p, and overexpression of BTG2 inhibited the protective effects of miR‑7‑5p. Finally, ICS II treatment resulted in the activation of the PI3K/Akt signaling pathway, which is essential for the survival of H9c2 cells under hypoxic conditions. In summary, ICS II reduces hypoxic injury in H9c2 cells via the miR‑7‑5p/BTG2 axis and activation of the PI3K/Akt signaling pathway.

Indexed as

AnimalsApoptosisCells, CulturedCell SurvivalFlavonoidsHypoxiaImmediate-Early ProteinsMicroRNAsMyocardial InfarctionMyocytes, CardiacPhosphatidylinositol 3-KinasesProto-Oncogene Proteins c-aktRatsSignal TransductionTumor Suppressor ProteinsUp-Regulationbaohuoside IBTG2 protein, ratFlavonoidsImmediate-Early ProteinsMicroRNAsPhosphatidylinositol 3-KinasesProto-Oncogene Proteins c-aktTumor Suppressor Proteins

Identifiers

PMID32945347
PMCPMC7447325
OpenAlexW3042981556

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.